Provided by Tiger Fintech (Singapore) Pte. Ltd.

NovoCure

21.32
+1.035.08%
Volume:714.57K
Turnover:14.71M
Market Cap:2.34B
PE:-13.63
High:21.32
Open:20.29
Low:20.07
Close:20.29
Loading ...

Novocure shares soar 33% as FDA approves lung cancer treatment

Investing.com
·
16 Oct 2024

Novocure upgraded to Buy from Neutral at H.C. Wainwright

TIPRANKS
·
16 Oct 2024

Stocks to Watch Wednesday: ASML, Morgan Stanley, Novocure, TSM -- WSJ

Dow Jones
·
16 Oct 2024

Stock Track | NovoCure Soars 30% on Landmark FDA Approval for Lung Cancer Treatment

Stock Track
·
16 Oct 2024

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?

Zacks
·
16 Oct 2024

24H|Chinese ADRs and ETFs Rally in Overnight Trading; YINN Soars 8%; KE Holdings Jumps 5%

Tiger Newspress
·
16 Oct 2024

Novocure Shares Soar 33% in Overnight Trading After FDA Approves Optune Lua Cancer Treatment

Dow Jones
·
16 Oct 2024

Buy Rating Affirmed for NovoCure as FDA Approval Expands Optune’s Market Potential

TIPRANKS
·
16 Oct 2024

NovoCure Says US FDA Approves Optune Lua to Treat Lung Cancer; Shares Jump After Hours

MT Newswires Live
·
16 Oct 2024

FDA approves Novocure’s Optune Lua in mNSCLC

TIPRANKS
·
16 Oct 2024

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

THOMSON REUTERS
·
16 Oct 2024

Novocure gets FDA approval for its lung cancer treatment

seekingalpha
·
16 Oct 2024

BRIEF-Novocure Ltd FDA Approves Optune Lua For Concurrent Use With Pd-1/Pd-L1 Inhibitors For Treatment Of Metastatic Non-Small Cell Lung Cancer

Reuters
·
16 Oct 2024

Novocure Ltd: FDA Approves Optune Lua for Concurrent Use With Pd-1/Pd-L1 Inhibitors for Treatment of Metastatic Non-Small Cell Lung Cancer

THOMSON REUTERS
·
16 Oct 2024

Novocure Ltd: Primary Endpoint of Study Was Achieved

THOMSON REUTERS
·
16 Oct 2024